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Abstract
OBJECTIVE—Copy number variations (CNVs) in the CYP2D6 gene contribute to 
interindividual variation in drug metabolism. Since the most common duplicated allele in Asian 
populations is the nonfunctional CYP2D6*36 allele, the goal of this study was to identify CNV 
assays that can differentiate between multiple copies of the CYP2D6*36 allele and multiple copies 
of other CYP2D6 alleles.
METHODS—We determined CYP2D6 gene copy numbers in 32 subjects with known CYP2D6 
CNVs from the Coriell Japanese-Chinese panel using four qRT-PCR assays. These assays target 
different regions of the CYP2D6 gene: 5′-flanking region (5′flank), intron 2 (Int2), intron 6 (Int6), 
and exon 9 (Ex9). The specific target site of the Ex9 assay was verified by sequencing the PCR 
amplicon.
RESULTS—Three of the CYP2D6 CNV assays (5′-flank, Int2, and Int6) estimated CYP2D6 copy 
numbers that were concordant for all 32 subjects. However, the Ex9 assay was concordant in only 
10 of 32 samples. The 10 concordant samples did not contain any CYP2D6*36 alleles and the 22 
discordant samples contained at least one CYP2D6*36 allele. Also, the Ex9 assay accurately 
quantified all of the non-CYP2D6*36 alleles in all samples. Ex9 amplicon sequencing indicated 
that it targets a region of CYP2D6 exon 9 that undergoes partial gene-conversion in the 
CYP2D6*36 allele.
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CONCLUSION—CYP2D6 Ex9 CNV assay can be used to determine the copy number of non-
CYP2D6*36 alleles. Selective amplification of non-CYP2D6*36 sequence by the Ex9 assay 
should be useful in determining the number of functional copies of CYP2D6 in Asian populations.
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INTRODUCTION
Copy number variation (CNV) involving deletion or multiplication of DNA segments is a 
primary source of variation in the human genome (1). Recent studies have suggested an 
increasing role for CNVs in many diseases including cancer, developmental diseases, mental 
illness, autoimmune diseases, and infectious diseases (2, 3). A number of genes involved in 
drug metabolism also exhibit copy number polymorphisms -- UGT2B17, UGT2B28 (4), 
SULTA1 (5), GSTT1, GSTM1 (6) and CYP2D6 (7, 8).
Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of ~20–25% of commonly 
prescribed drugs (9). Its activity is affected by environmental and genetic factors that lead to 
large interindividual variability in drug metabolism (10, 11). Genetically, CYP2D6 is highly 
polymorphic; variants include single nucleotide polymorphisms (SNPs), insertions, 
deletions, as well as, copy number variations resulting from CYP2D6 gene deletion or 
multiplication. Not all CNVs are functionally similar; CNVs in CYP2D6 gene can cause 
either reduced metabolism (gene deletions) or increased metabolism (>2 functional copies). 
The frequencies of CYP2D6 CNVs vary considerably between ethnic populations (7, 8). For 
example, the frequency of the CYP2D6 whole gene deletion (CYP2D6*5) ranges from 1–7% 
in all the three major ethnic populations (7) and the frequency of CYP2D6 gene 
multiplication is as high as 45% in Asians (12). The genetics of CYP2D6 are further 
complicated by the variety of CYP2D6 alleles that exist as multiple copies. While the 
functional CYP2D6*1 and *2 duplications are frequent among all ethnicities (7, 8), the 
nonfunctional CYP2D6*4 and *36 allele duplications are more common among Caucasians 
(7) and Asians (12, 13), respectively. These studies emphasize that the number of copies of a 
gene detected by the CNV assays cannot reasonably be used to estimate the phenotypic 
consequence without identification of the sequence of each copy.
The currently available genome-wide association studies (GWAS) arrays have relatively few 
probes covering the CYP2D6 locus, and thus are insensitive for accurately identifying allele 
specific CYP2D6 CNVs. The determination of CYP2D6 gene copy number is also 
complicated by the presence of highly homologous pseudogenes, CYP2D8 and CYP2D7 and 
by the presence of CYP2D6-CYP2D7 fusion genes like CYP2D6*36, which includes the 5′ 
end of the CYP2D6 gene fused with the 3′end of the CYP2D7 gene due to gene-
recombination. Furthermore, because of the large sizes of CYP2D6 gene deletion and 
duplications, relatively difficult techniques including long-template PCR and Southern 
blotting are commonly used for copy number estimation (14). Recently, several qRT-PCR 
assays have been reported (12, 14, 15). Commercial qRT-PCR assays have also become 
available; however, since the exact positions of the target sequences are not provided for 
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these assays, their ability to distinguish between specific alleles and fusion genes must be 
determined experimentally. Since our preliminary studies showed discrepancies between 
some of the qRT-PCR assays, the objective of this study was to evaluate the ability of 
several of these assays to amplify several different CYP2D6 alleles. The results of our study 
suggest that assay selection is important for the accurate determination of CYP2D6 gene 
copy number.
METHODS
Samples
We used 17 Japanese and 15 Chinese (JCH) genomic DNA samples from the HapMap 
human diversity panel (Coriell Institute for Medical Research, Camden, NJ, USA) for our 
copy number assays. We have previously reported the CYP2D6 gene copy number for these 
samples (12).
Copy number assays
To assess the CYP2D6 gene copy number, we used four assays: two commercial quantitative 
TaqMan Copy Number Assays (assay ids: Hs00010001_cn (Ex9) and Hs04502391_cn 
(Int6); Applied Biosystems, Forest City, CA, USA) and two assays (5′-flank and Int2) 
described by Hosono et al., (12). All four assays were performed along with an internal 
control - RNaseP TaqMan Copy Number Reference Assay (assay id: 4403326; Applied 
Biosystems, Forest City, CA, USA). All assays were performed in quadruplicates in a 
StepOne Plus PCR instrument (Applied Biosystems, Forest City, CA, USA). The assays 
were performed with TaqMan Genotyping PCR Master Mix (Applied Biosystems, Forest 
City, CA, USA) using 20 ng of genomic DNA in a 20 μL reaction. The cycling conditions 
were: 95°C for 10 min for initial denaturation and enzyme activation, followed by 40 cycles 
each of 95°C for 15 s and 60°C for 1 min. Relative quantification (RQ) was performed using 
CopyCaller Software (Applied Biosystems, Forest City, CA, USA), following the 
comparative ΔΔCT method. NA18529 (2 copies) and NA18968 (3 copies) DNA samples 
were used as controls based on our previous results (12). The data is reported as the 
estimated number of CYP2D6 copies, with the error bars representing the estimated copy 
numbers range. As a quality control measure, we repeated all four assays in 10% of the 
samples. All repeated assays yielded concordant results.
Cloning and Sequencing
To determine the target site of the Ex9 assay, we cloned the PCR product using the 
pCR8/GW/TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA, USA). The clones were 
sequenced at the Indiana University DNA Sequencing Core Facility.
RESULTS
We estimated CYP2D6 gene copy number in 32 genomic DNA samples from the Coriell 
Japanese-Chinese Repository using four different qRT-PCR assays – two assays that target 
intron 6 and exon 9 (Int6 and Ex9; Applied Biosystems, Forest City, CA, USA) and two 
assays that target the 5′-flanking region and intron 2 (Int2 and 5′-flank; (12)). The estimated 
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CYP2D6 gene copy numbers from three of the assays, 5′-flank, Int2 and Int6, were the same 
in all the samples (Figure 1). However, the Ex9 assay was concordant in only 10 (31%) of 
the 32 samples. Based on our previous results (12), all the 22 samples that were discordant 
contained at least one CYP2D6*36 allele. Since the CYP2D6*36 allele contains a gene 
conversion in exon 9, we cloned and sequenced the PCR amplicon from the Ex9 assay. The 
amplicon sequence corresponds to nucleotides 5735-5795 (61 bp) of GenBank accession # 
M33388.1 (Figure 2). This region is a part of the CYP2D6*36 allele that contains the 
CYP2D7 sequence due to partial gene recombination. The PCR amplicon sequence was that 
of CYP2D6, and not CYP2D7.
DISCUSSION
The results from our studies indicate the importance of selecting the appropriate assay when 
determining the CYP2D6 gene copy number. Multiple assays exist, and they may serve 
different purposes. Three of the four assays that we tested estimated the same CYP2D6 gene 
copy numbers in all the samples, presumably all copies of CYP2D6 (*1, *2, *36 and *10) 
irrespective of the allele involved in the CNV. These copy number estimations were 
concordant with our previous results (12). In contrast, the CYP2D6 gene copy number 
estimated by one of the commercial assays (Ex9) was discordant with the other three assays. 
The Ex9 assay detected all of the alleles, except the CYP2D6*36 allele. The lack of 
detection of CYP2D6*36 is likely because the reverse primer of the assay lies in a region of 
CYP2D6 exon 9 that has a different sequence in the CYP2D6*36 allele due to gene-
conversion to CYP2D7. Although the exact primer sequences and locations of the amplicon 
are not provided for the Ex9 assay, by cloning and resequencing, we determined the 
sequence of the target region. The Ex9 assay target sequence appears to be located within 
the sequence targeted by the assay described by Schaeffeler et al., (15), but the primers are 
not the same. Therefore, the Ex9 assay would not be useful in detecting the total number of 
CYP2D6 alleles in Asian populations where the CYP2D6*36 allele is common. However, 
since the CYP2D6*36 allele is a nonfunctional allele, the Ex9 assay should give a better 
estimation of the number of functional copies, particularly in Asian population. An 
exception would be other rare nonfunctional alleles, such as CYP2D6*4 which is present in 
<1% frequency in Asians; this allele would also be detected by the Ex9 assay. When 
combined with one of the other copy number assays, the Ex9 assay can be indirectly used to 
identify the number of CY2D6*36 alleles. Since the current method for CYP2D6*10 
genotyping is the presence of the SNP, 100T, a mutation which is also present in 
CYP2D6*36, Ex9 copy number assay should help to distinguish between *10 and *36 
alleles. In populations where the CYP2D6*36 alleles are quite rare, such as the Caucasian 
and African American populations, all four assays studied are likely to produce similar 
results. Our results also indicate that all these assays should also be useful in detecting the 
CYP2D6*5 (gene deletion) in samples that have only one copy due to a whole gene deletion 
in CYP2D6*5. In conclusion, these results indicate that it is critical that copy number assays 
are designed to target appropriate regions of the CYP2D6 gene. Not all copy number 
variants are the same and interpretable data may not be obtained if CNV assays for any gene 
are not appropriately targeted.
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Figure 1. Comparison of estimated CYP2D6 gene copy numbers using four copy number assays
CYP2D6 copy numbers (y-axis) were estimated using CNV assays that target the 5′flanking 
region (blue), intron 2 (brown), intron 6 (gray), and exon 9 (black). Also included are the 
known copy numbers (cross hatched) from Hosono et al., (12). The sample identification 
numbers (x-axis) are those from the Coriell JCH diversity panel (each of the numbers are 
preceded by an NA). The number of * next to each sample indicates the number of 
CYP2D6*36 alleles present based on data from Hosono et al., (12). Each sample was 
assayed in quadruplicate for each of the four assays. The data presented are the mean 
CYP2D6 copy number with the error bars representing the range of copy numbers estimated 
for each assay.
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Figure 2. Sequence alignment of the Ex9 assay amplicon with the CYP2D6, CYP2D7and CYP2D8 
exon 9 region
A portion of the exon 9 sequence from CYP2D6*1, CYP2D6*36, and the corresponding 
regions from CYP2D7 and CYP2D8 pseudogenes are shown. This corresponds to 
nucleotides 5700-5819 (120 bp) of M33388.1. The sequence of the Ex9 assay amplicon is 
highlighted in gray and the position of the assay described by Schaeffeler et al., (15) is 
underlined. The lower case letters indicate differences from the CYP2D6 gene. * indicates 
DNA sequence conservation across all four genes.
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